4D MOLECULAR THERAPEUTICS INC (FDMT)
Health Care · Gene therapy / AAV-based therapeutics for retinal and genetic diseases · NASDAQ
4D Molecular Therapeutics is a clinical-stage biotech developing AAV-based gene therapies for ophthalmic and respiratory diseases using its proprietary directed-evolution vector platform.
What 4D MOLECULAR THERAPEUTICS INC does
4D Molecular Therapeutics is a late-stage biotechnology company developing durable, gene-therapy-based therapeutics targeting retinal vascular diseases and genetic lung diseases. Its lead program, 4D-150, utilizes a proprietary AAV vector platform to deliver anti-VEGF biologics and RNA interference for wet age-related macular degeneration and diabetic macular edema, with Phase 3 trials underway. The company is also advancing pipeline programs including 4D-175 for geographic atrophy, 4D-710 for cystic fibrosis lung disease, and 4D-725 for alpha-1 antitrypsin deficiency lung disease, primarily through strategic partnerships.
Themes: Gene therapy / AAV vectors, Retinal vascular diseases (wet AMD, DME), Genetic lung diseases (CF, A1AT deficiency), Anti-VEGF therapeutics, RNAi / RNA interference
Fundamentals
- Price$15.83 as of 2026-08-21 close
- Market cap$788M as of 2026-08-21
- 1-year return+131.1% 2025-08-21 close $6.85 → 2026-08-21 close $15.83
- P/En/a negative earnings
- Net margin-182.3% as of 2026-08-24
- ROE-36.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue CAGR (3y)+200.9% SEC XBRL
- Beta2.77 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How FDMT compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How 4D MOLECULAR THERAPEUTICS INC looks technically
4D MOLECULAR THERAPEUTICS INC (FDMT) is trading 59.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 246 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 74, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 59.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +59.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $11.51 | $11.51 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $9.94 | $9.94 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 9.39. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 246 trading days ago — a "golden cross", a bullish long-term signal | 246 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 59.3% above | +59.3% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with buyers in control | 32.5 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 74, in overbought territory (above 70) | 73.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($10.06 to $16.93) — its "stochastic" reading is 84 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 84.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $16.93 | $16.93 |
|---|---|---|
| From the 52-week high | it is 6.5% below its 52-week high (its highest price of the past year) | -6.5% |
| Above the 52-week low | it is 165.2% above its 52-week low (its lowest price of the past year) | +165.2% |
| Below the 52-week high | it is 6.5% below its highest point of the past year | 6.5% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $54.98 (set on 2021-03-10) | $54.98 |
| Given back of the 52-week move | over the past year its closes ranged ($6.14 to $16.76), and it has given back only a small part of its rise from last year’s low — 9% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $9.86 to $10.20. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 8.8% |
| From the all-time high | it is 71.2% below its all-time high | -71.2% |
| Nearest price level | it is trading 24.9% above a support level at $11.89 — a price it turned at three times since 2025-11-28, most recently on 2026-07-21. Since 2024-08-21 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -24.9% |
| All-time low | its lowest closing price on record is $2.23 (set on 2025-04-09) | $2.23 |
| Above the all-time low | it is 608.3% above its all-time low | +608.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.03 between its high and its low — about 6.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.03 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $7.39 and $16.44 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $7.39 – $11.91 – $16.44 |
| Typical daily range (% of price) | its price moves about 6.5% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.5% |
| Stretch from the 200-day average | it is trading 5.7 daily ranges above its 200-day average price (59.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.08× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.4% |
|---|---|---|
| Open gap | it gapped 3.3% above the previous close 2 sessions ago and has not traded back through the level it left behind at 14.72 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.3% |
| Gap filled | a 2.0% gap down opened on 2026-08-18 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 3 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -5.55% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 36.8 percentage points (the stock gained 39.2% while the market gained 2.3%) | +36.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 79.1 percentage points (the stock gained 82.2% while the market gained 3.1%) | +79.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 64.4 percentage points (the stock gained 75.5% while the market gained 11.1%) | +64.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 110.6 percentage points (the stock gained 131.1% while the market gained 20.5%) | +110.6% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 36% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.7% of the share price. | +36.1% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 55% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $10.24 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +54.6% |
|---|
Price levels it has turned at before
FDMT last closed at $15.83 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $11.89 | Support | 24.9% below the last close | turned there three times · 2025-11-28 to 2026-07-21 |
| $10.72 | Support | 32.3% below the last close | turned there twice · 2026-03-26 to 2026-04-17 |
| $9.81 | Support | 38.0% below the last close | turned there four times · 2025-11-10 to 2026-02-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $9.39.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $15.02 and $18.50 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $9.39.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$29.10 range $18.00 – $37.00; median $30.50
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for FDMT
- Consensus EPS estimate-$1.04 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["No approved products or product revenue; entirely dependent on successful development and regulatory approval of pipeline candidates, particularly 4D-150, with Phase 3 results not expected until 2027","Recurring net losses totaling $716.3 million accumulated deficit; continued significant cash burn expected with no near-term revenue generation; substantial capital requirements for ongoing clinical development and manufacturing scale-up","Gene therapy safety and manufacturing risks, including prior cases of intraocular inflammation in retinal programs and complexities in AAV vector manufacturing and commercial-scale production"]
What changed in the latest 10-Q
AI-assisted comparison of FDMT's 10-Q filed 2026-05-07 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- 4D-150 enrollment completion announced in February 2026 within approximately 11-month period, ahead of initial projections (newer filing, filed 2026-05-07)
- 4FRONT-1 clinical trial expected to exceed 500 patients randomized (newer filing, filed 2026-05-07)
- 4FRONT-2 enrollment completion expected in second half of 2026 with topline data anticipated in second half of 2027 (newer filing, filed 2026-05-07)
- 4D-175 described as utilizing intravitreal R100 AAV vector with codon-optimized transgene encoding shortened form of human complement factor H (newer filing, filed 2026-05-07)
- 4D-710 described as currently in Phase 2 development (newer filing, filed 2026-05-07)
- Net losses of $68.8 million for three months ended March 31, 2026 and accumulated deficit of $785.1 million as of March 31, 2026 (newer filing, filed 2026-05-07)
- Description of CFF funding agreement with $11.0 million (with $7.5 million in initial tranche completed in October 2025) (newer filing, filed 2026-05-07)
- Removed:
- Strategic pipeline prioritization language from January 2025 discussing seeking strategic alternatives for 4D-175 and 4D-725, and termination of 4D-110 and 4D-125 (older filing, filed 2025-11-10)
- October 2025 announcement that enrollment was exceeding initial projections with more than 200 patients enrolled in 4FRONT-1 (older filing, filed 2025-11-10)
- Reference to 52-week topline data for 4FRONT-1 in first half of 2027 as acceleration from previous guidance to second half of 2027 (older filing, filed 2025-11-10)
- 4FRONT-2 identical design language and enrollment of treatment naïve and recently diagnosed, treatment-experienced patients (older filing, filed 2025-11-10)
- Description of 4D-710 as 'second priority product candidate' (older filing, filed 2025-11-10)
- Reference to 'durable expression' of CFTR transgene in newer filing changes to only 'successful delivery' (older filing, filed 2025-11-10)
- November 2025 completed underwritten offering details (8,385,809 shares at $10.51, pre-funded warrants, $93.3 million net proceeds) (older filing, filed 2025-11-10)
- Net losses of $56.9 million and $43.8 million for three months ended September 30, 2025 and 2024, and $159.5 million and $111.2 million for nine months (older filing, filed 2025-11-10)
- Accumulated deficit of $735.7 million as of September 30, 2025 (older filing, filed 2025-11-10)
- Reworded:
- Otsuka agreement description changed from 'ophthalmological diseases' to 'retinal vascular diseases' to specify scope (newer vs older)
- Otsuka territory reference changed from 'APAC region' to 'Otsuka Territory' and 'Asia-Pacific markets' for consistency (newer vs older)
- Reference to 'durable expression' removed and changed to focus on 'successful delivery and durable expression' in context of CFTR transgene (newer vs older)
- 4D-150 transgene description changed from 'transgene cassette encoding aflibercept and inhibitory miRNA targeting VEGF-C' to 'transgene encoding anti-VEGF biologics: aflibercept and an RNA interference (RNAi) approach targeting VEGF-C' (newer vs older)
- 4D-150 development goal changed from 'become the first backbone therapy' to 'transform the standard of care for large market retinal vascular diseases with a safe, in-office, and durable lifelong backbone therapy' (newer vs older)
- Pipeline focus statement changed from 'core pipeline focus is advancing 4D-150 and 4D-710' to describing advancement of 4D-150 through late-stage studies and commercialization, with other programs through strategic funding alternatives (newer vs older)
- CFF funding agreement amount described as '$11.0 million' in newer filing vs '$11 million' in older filing (newer vs older)
- Notes:
- The older filing text appears truncated at the end ('Our net losse'), limiting full comparison of financial loss discussion sections
- The newer filing text also appears truncated at the end ('We will r'), limiting complete assessment of later MD&A sections
- Filing dates are different (2026-05-07 vs 2025-11-10) with different reporting periods (March 31, 2026 vs September 30, 2025), which accounts for some of the updates to financial figures and clinical trial progress
Risk Factors
- Added:
- Added reference to 'condensed financial statements' in opening paragraph (newer filing, 2026-05-07)
- Added bullet point about being 'adversely impacted by general economic conditions, such as rising inflation, tariffs and increased interest rates' (newer filing, 2026-05-07)
- Added bullet point about 'experience delays in our preclinical studies and clinical trials, whether current or planned, due to pandemics or public health emergencies' (newer filing, 2026-05-07)
- Added disclosure of cash position: '$457.6 million in cash and cash equivalents and marketable securities as of March 31, 2026' (newer filing, 2026-05-07)
- Added runway disclosure: 'we believe that our existing cash, cash equivalents and marketable securities will allow us to fund our planned operations for at least one year from the date of the issuance of the condensed financial statements' (newer filing, 2026-05-07)
- Removed:
- Removed 'Risk Factor Summary' section that was present in older filing (older filing, 2025-11-10)
- Removed specific financial metrics for nine-month period: '$159.5 million and $111.2 million for the nine months ended September 30, 2025 and 2024' (older filing, 2025-11-10)
- Removed phrase 'including for our product candidates and our Therapeutic Vector Evolution platform' from description of resource devotion (older filing, 2025-11-10)
- Reworded:
- Changed 'leading late-stage biotechnology' to 'leading late-stage biotechnology company' (newer filing, 2026-05-07)
- Changed 'with potential' to 'with the potential' (newer filing, 2026-05-07)
- Updated net loss figures from three months ended September 30, 2025 and 2024 ($56.9 million and $43.8 million) to three months ended March 31, 2026 and 2025 ($68.8 million and $48.0 million) (newer filing, 2026-05-07)
- Updated accumulated deficit from $735.7 million as of September 30, 2025 to $785.1 million as of March 31, 2026 (newer filing, 2026-05-07)
- Changed bullet point from 'expand our manufacturing facilities and work with our contract manufacturers to scale up the manufacturing processes for our product candidates' to include 'continue our research and discovery activities' and 'continue the development of our Therapeutic Vector Evolution platform' as separate bullet points (newer filing, 2026-05-07)
- Notes:
- The newer filing appears to be truncated mid-sentence ('Our ability to raise additional capital may be adversel'), making complete comparison difficult at the end of the provided text
- Older filing contained a 'Risk Factor Summary' section not present in newer filing; this represents a structural change rather than content change
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 9 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 2 sells ($399319) — 1 selling insider
- Last 90 days0 buys · 9 sells ($3M) — 2 selling insiders
- Last 180 days0 buys · 9 sells ($3M) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-04. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about FDMT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding FDMT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 7,818,636
- Reported value $72,791,495
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
FDMT had 12,038,453 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for FDMT because the newest share count we hold predates that settlement by more than 180 days, and a buyback or issuance in between would move the base. The reported figures above are unaffected.
- Reported short interest (shares) 12,038,453
- Prior settlement (shares) 11,363,434
- Reported change 5.94%
- Days to cover (reported) 17.69
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Regeneron (REGN)
- Roche (RHHBY)
- Novartis (NVS)
- Astellas Pharma (ALPMY)
- Spark Therapeutics (owned by Roche)
- REGENXBIO (RGNX)
- Adverum Biotechnologies (ADVM)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare FDMT vs…
FDMT ranks in…
Frequently asked questions
What does 4D MOLECULAR THERAPEUTICS INC (FDMT) do?
4D Molecular Therapeutics is a late-stage biotechnology company developing durable, gene-therapy-based therapeutics targeting retinal vascular diseases and genetic lung diseases. Its lead program, 4D-150, utilizes a proprietary AAV vector platform to deliver anti-VEGF biologics and RNA interference for wet age-related macular degeneration and diabetic macular edema, with Phase 3 trials underway.
What sector is 4D MOLECULAR THERAPEUTICS INC (FDMT) in?
4D MOLECULAR THERAPEUTICS INC (FDMT) is classified in the Health Care sector. Its industry is Gene therapy / AAV-based therapeutics for retinal and genetic diseases. It trades on NASDAQ.
Who are 4D MOLECULAR THERAPEUTICS INC's (FDMT) competitors?
Notable peers of 4D MOLECULAR THERAPEUTICS INC (FDMT) include Regeneron, Roche, Novartis, Astellas Pharma and Spark Therapeutics (owned by Roche). This peer set is informational only — not financial advice.
Is 4D MOLECULAR THERAPEUTICS INC (FDMT) overbought or oversold right now?
4D MOLECULAR THERAPEUTICS INC (FDMT) is currently in overbought territory (its 14-day RSI is 74, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on FDMT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.